Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cocrystal Pharma, Inc.COCP · Entity 7621 | President and Co-CEO | January 09, 2026 | January 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cocrystal Pharma, Inc.
Report date January 09, 2026 · Filed January 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.10 · Expires 2036-01-09 | Direct | 49,229 |
Reported balance
After 2026-01-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-09 · Grant · Acquired 49,229 · Balance 49,229 F1: The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as an officer of the Issuer on each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as an officer of the Issuer on each applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 09, 2026 Filed Jan 13, 2026 21:10 UTC | Cocrystal Pharma, Inc. COCP · Entity 7621 | GrantStock Options (Right to Buy) · Derivative | 49,229 | $0.00 Strike: $1.10 | $0.00 |
DisclosureSEC source: 0001493152-26-002038 · ownership.xml · derivative · entry 1 Lee Sam · CIK 0001602074 · President and Co-CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,229 Underlying: Common Stock · 49,229 shares Expires 2036-01-09 F1 · security: The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as an officer of the Issuer on each applicable vesting date. F1 · derivative.exercise_date: The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as an officer of the Issuer on each applicable vesting date. Read SEC document |
| October 09, 2024 Filed Oct 11, 2024 20:05 UTC | Cocrystal Pharma, Inc. COCP · Entity 7621 | GrantCommon Stock | 40,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-24-040904 · ownership.xml · nonDerivative · entry 1 Lee Sam · CIK 0001602074 · President and Co-CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,355 F1 · security: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The grant is exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by the Board of Directors of the Issuer. One half of the RSUs are fully vested, with the balance vesting in eight equal quarterly installments on the last day of each quarter commencing with the quarter ending September 30, 2025, subject to continued services for the Company as of each applicable vesting date. Shares of common stock will be delivered to the Reporting Person promptly upon vesting, unless the Reporting Person elects to defer delivery. The RSUs were granted under the Issuer's 2015 Equity Incentive Plan and will vest in full upon a Change of Control as defined in such Plan. F1 · price: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The grant is exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by the Board of Directors of the Issuer. One half of the RSUs are fully vested, with the balance vesting in eight equal quarterly installments on the last day of each quarter commencing with the quarter ending September 30, 2025, subject to continued services for the Company as of each applicable vesting date. Shares of common stock will be delivered to the Reporting Person promptly upon vesting, unless the Reporting Person elects to defer delivery. The RSUs were granted under the Issuer's 2015 Equity Incentive Plan and will vest in full upon a Change of Control as defined in such Plan. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 20:05 UTC | Cocrystal Pharma, Inc. COCP · Entity 7621 | GrantStock Options (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.67 | $0.00 |
DisclosureSEC source: 0001493152-23-025082 · ownership.xml · derivative · entry 1 Lee Sam · CIK 0001602074 · President and Co-CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-07-18 F1 · security: The stock options were issued pursuant to the 2015 Equity Incentive Plan and are intended to be incentive stock options within the meaning of Section 422 of the Internal Revenue Code (the "Code"). F2 · derivative.exercise_date: The stock options vest and become exercisable as follows, subject in each case to the limitations on exercisability of incentive stock options under Section 422 of the Code: one-half will vest on July 18, 2024 and the remaining half will vest in eight equal quarterly installments on the last day of March, June, September, and December commencing on September 30, 2024, subject to continued employment on each applicable vesting date. Read SEC document |
| July 25, 2022 Filed Aug 3, 2022 20:02 UTC | Cocrystal Pharma, Inc. COCP · Entity 7621 | GrantStock Options (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $0.42 | $0.00 |
DisclosureSEC source: 0001493152-22-021148 · ownership.xml · derivative · entry 1 Lee Sam · CIK 0001602074 · President and Co-Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2032-07-25 F1 · security: The stock options were issued pursuant to the 2015 Equity Incentive Plan and are intended to be incentive stock options within the meaning of Section 422 of the Internal Revenue Code (the "Code"). F2 · derivative.exercise_date: The stock options vest and become exercisable as follows, subject in each case to the limitations on exercisability of incentive stock options under Section 422 of the Code: one-half will vest on July 25, 2023 and the remaining half will vest in eight equal quarterly installments on the last day of March, June, September, and December commencing on September 30, 2023, subject to continued employment on each applicable vesting date. Read SEC document |
| July 16, 2021 Filed Jul 20, 2021 20:05 UTC | Cocrystal Pharma, Inc. COCP · Entity 7621 | GrantStock Options (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001493152-21-017331 · ownership.xml · derivative · entry 1 Lee Sam · CIK 0001602074 · President and Co-Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2031-07-16 F1 · security: The stock options were issued pursuant to the 2015 Equity Incentive Plan and are intended to be incentive stock options within the meaning of Section 422 of the Internal Revenue Code (the "Code"). F2 · derivative.exercise_date: The stock options vest and become exercisable as follows, subject in each case to the limitations on exercisability of incentive stock options under Section 422 of the Code: one-half will vest on July 16, 2022 and the remaining half will vest in eight equal quarterly installments on the last day of March, June, September, and December commencing on September 30, 2022, subject to continued employment on each applicable vesting date. Read SEC document |
| November 24, 2020 Filed Feb 12, 2021 22:02 UTC | Cocrystal Pharma, Inc. COCP · Entity 7621 | GrantStock Options (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.30 | $0.00 |
DisclosureSEC source: 0001493152-21-003686 · ownership.xml · derivative · entry 1 Lee Sam · CIK 0001602074 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-11-24 F1 · security: The stock options were issued pursuant to the 2015 Equity Incentive Plan and are intended to be incentive stock options within the meaning of Section 422 of the Internal Revenue Code. F2 · derivative.exercise_date: The stock options vest as follows: 25,000 incentive stock options will vest on the one year anniversary of the grant date and the remaining 25,000 incentive stock options will vest in eight equal quarterly increments with the first such quarterly increment vesting on February 28, 2022, subject to continued employment on each applicable vesting date. Read SEC document |
| June 22, 2020 Filed Jun 24, 2020 22:52 UTC | Cocrystal Pharma, Inc. COCP · Entity 7621 | GrantStock Options (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $1.33 | $0.00 |
DisclosureSEC source: 0001493152-20-011752 · ownership.xml · derivative · entry 1 Lee Sam · CIK 0001602074 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-06-22 F1 · security: The stock options are intended to be incentive stock options within the meaning of Section 422 of the Internal Revenue Code. F2 · derivative.exercise_date: The stock options vest as follows: 50,000 stock options will vest on the one year anniversary of the grant date and the remaining 50,000 stock options will vest in eight equal quarterly increments with the first such quarterly increment vesting on September 30, 2021. Read SEC document |
| September 21, 2018 Filed Sep 24, 2018 20:52 UTC | Cocrystal Pharma, Inc. COCP · Entity 7621 | GrantStock Options (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0001493152-18-013671 · ownership.xml · derivative · entry 1 Lee Sam · CIK 0001602074 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-09-20 F1 · security: The stock options vest as follows: 1/4 will vest on the one year anniversary of the grant date and the remaining 3/4 will vest in 12 equal quarterly increments. F2 · derivative.exercise_date: The stock options are intended to be incentive stock options within the meaning of Section 422 of the Internal Revenue Code. Only $100,000 (or 35,971 options) may first become exercisable by the Reporting Person in each calendar year. Read SEC document |
| December 23, 2016 Filed Dec 23, 2016 21:05 UTC | Cocrystal Pharma, Inc. COCP · Entity 7621 | SaleCommon Stock | 2,200,000 | $0.44 | $968,000.00 |
DisclosureSEC source: 0001415889-16-007631 · form4-12232016_041201.xml · nonDerivative · entry 1 Lee Sam · CIK 0001602074 · PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,087,847 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.